Histamine H3 Receptor: A Potential Drug Target for the Treatment of Central Nervous System Disorders

Authors: Alguacil L.F.¹; Perez-Garcia C.¹

Source: Current Drug Targets-CNS & Neurological Disorders, Volume 2, Number 5, October 2003 , pp. 303-313(11)

Publisher: Bentham Science Publishers

Key:

- Free Content

- New Content

- Subscribed Content

- Free Trial Content

Abstract:

Histamine H3 receptors were first described in the eighties but finally cloned four years ago. They are G-protein coupled, mostly presynaptic, and are involved in the control of the synthesis and / or release of different neurotransmitters both in the central nervous system and the periphery. The availabiliy of specific ligands has permitted the study of potential therapeutic applications of either stimulating or blocking the function of these receptors. There is experimental evidence that drugs targeted at histamine H3 receptors could be beneficial for neurodegenerative diseases such as Alzheimer and Parkinson's disease, epilepsy, drug abuse and several affective, appetite and sleeping disorders, among others. This review presents recent advances in this field.

Keywords: histamine h3 receptor; appetite disorders; sleeping disorders; neurodegenerative disorders; depression

Document Type: Review article

DOI: 10.2174/1568007033482760

Affiliations: 1: Universidad San Pablo CEU, Urb. Monteprincipe, 28668 Boadilla, Madrid, Spain.

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$55.10 plus tax Refund Policy